Products - Children and young people | Topic | NICE

Showing 191 products

Date | Title

Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
Product type:
Guidance
Programme:
Technology appraisal guidance
Expected publication date:
28 July 2021
Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)
Product type:
Guidance
Programme:
Highly specialised technologies guidance
Last updated:
20 September 2024
Published:
10 October 2018
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) (TA982)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 June 2024
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over (TA977)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 May 2024
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under (TA975)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 May 2024
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal) (TA945)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 January 2024
Risdiplam for treating spinal muscular atrophy (TA755)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
15 December 2023
Published:
16 December 2021
Transient loss of consciousness ('blackouts') in over 16s (CG109)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
21 November 2023
Published:
25 August 2010
Suspected cancer: recognition and referral (NG12)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
2 October 2023
Published:
23 June 2015
Guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of anxiety or low mood: early value assessment (HTE3)
Product type:
Guidance
Programme:
Health technology evaluation
Last updated:
5 September 2023
Published:
8 February 2023
Otitis media with effusion in under 12s (NG233)
Product type:
Guidance
Programme:
NICE guideline
Published:
30 August 2023
Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) (TA910)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 July 2023
Minimally invasive fusionless posterior-approach surgery to correct idiopathic scoliosis in children and young people (IPG765)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 June 2023
Atopic eczema in under 12s: diagnosis and management (CG57)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
7 June 2023
Published:
12 December 2007
Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
11 May 2023
Published:
1 August 2015
Asfotase alfa for treating paediatric-onset hypophosphatasia (HST23)
Product type:
Guidance
Programme:
Highly specialised technologies guidance
Published:
1 March 2023
Somatrogon for treating growth disturbance in children and young people aged 3 years and over (TA863)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 February 2023
Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education (NG213)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
13 January 2023
Published:
9 March 2022
Self-harm: assessment, management and preventing recurrence (NG225)
Product type:
Guidance
Programme:
NICE guideline
Published:
7 September 2022
Urinary tract infection in under 16s: diagnosis and management (NG224)
Product type:
Guidance
Programme:
NICE guideline
Published:
27 July 2022
Fenfluramine for treating seizures associated with Dravet syndrome (TA808)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 July 2022
Social, emotional and mental wellbeing in primary and secondary education (NG223)
Product type:
Guidance
Programme:
NICE guideline
Published:
6 July 2022
Vertebral body tethering for idiopathic scoliosis in children and young people (IPG728)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
29 June 2022
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over (HST20)
Product type:
Guidance
Programme:
Highly specialised technologies guidance
Published:
5 May 2022
Epilepsies in children, young people and adults (NG217)
Product type:
Guidance
Programme:
NICE guideline
Published:
27 April 2022
Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)
Product type:
Guidance
Programme:
Highly specialised technologies guidance
Published:
28 March 2022
Palforzia for treating peanut allergy in children and young people (TA769)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 February 2022
Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) (TA749)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 December 2021
Fever in under 5s: assessment and initial management (NG143)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
26 November 2021
Published:
7 November 2019
Looked-after children and young people (NG205)
Product type:
Guidance
Programme:
NICE guideline
Published:
20 October 2021
Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 October 2021
Babies, children and young people's experience of healthcare (NG204)
Product type:
Guidance
Programme:
NICE guideline
Published:
25 August 2021
Bronchiolitis in children: diagnosis and management (NG9)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
9 August 2021
Published:
1 June 2015
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) (TA714)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 July 2021
Autism spectrum disorder in under 19s: support and management (CG170)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
14 June 2021
Published:
28 August 2013
Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
22 March 2021
Published:
29 November 2017
Cannabis-based medicinal products (NG144)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
22 March 2021
Published:
11 November 2019
Eating disorders: recognition and treatment (NG69)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
16 December 2020
Published:
23 May 2017
Intravenous fluid therapy in children and young people in hospital (NG29)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
11 June 2020
Published:
9 December 2015
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 December 2019
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 December 2019
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)
Product type:
Guidance
Programme:
Highly specialised technologies guidance
Published:
27 November 2019
Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NG1)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
9 October 2019
Published:
14 January 2015
Attention deficit hyperactivity disorder: diagnosis and management (NG87)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
13 September 2019
Published:
14 March 2018
End of life care for infants, children and young people with life-limiting conditions: planning and management (NG61)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
25 July 2019
Published:
7 December 2016
Depression in children and young people: identification and management (NG134)
Product type:
Guidance
Programme:
NICE guideline
Published:
25 June 2019
Cochlear implants for children and adults with severe to profound deafness (TA566)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 March 2019
Cough (acute): antimicrobial prescribing (NG120)
Product type:
Guidance
Programme:
NICE guideline
Published:
7 February 2019
Dinutuximab beta for treating neuroblastoma (TA538)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 August 2018
Learning disabilities and behaviour that challenges: service design and delivery (NG93)
Product type:
Guidance
Programme:
NICE guideline
Published:
28 March 2018
Autism spectrum disorder in under 19s: recognition, referral and diagnosis (CG128)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
20 December 2017
Published:
28 September 2011
Immunosuppressive therapy for kidney transplant in children and young people (TA482)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 October 2017
Child abuse and neglect (NG76)
Product type:
Guidance
Programme:
NICE guideline
Published:
9 October 2017
Child maltreatment: when to suspect maltreatment in under 18s (CG89)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
9 October 2017
Published:
22 July 2009
Faltering growth: recognition and management of faltering growth in children (NG75)
Product type:
Guidance
Programme:
NICE guideline
Published:
27 September 2017
Developmental follow-up of children and young people born preterm (NG72)
Product type:
Guidance
Programme:
NICE guideline
Published:
9 August 2017
Constipation in children and young people: diagnosis and management (CG99)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
13 July 2017
Published:
26 May 2010
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 July 2017
Antisocial behaviour and conduct disorders in children and young people: recognition and management (CG158)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
19 April 2017
Published:
27 March 2013
Cerebral palsy in under 25s: assessment and management (NG62)
Product type:
Guidance
Programme:
NICE guideline
Published:
25 January 2017
Spasticity in under 19s: management (CG145)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
29 November 2016
Published:
25 July 2012
Psychosis and schizophrenia in children and young people: recognition and management (CG155)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
26 October 2016
Published:
23 January 2013
Harmful sexual behaviour among children and young people (NG55)
Product type:
Guidance
Programme:
NICE guideline
Published:
20 September 2016
Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures (CG64)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
8 July 2016
Published:
17 March 2008
Transition from children’s to adults’ services for young people using health or social care services (NG43)
Product type:
Guidance
Programme:
NICE guideline
Published:
24 February 2016
Children’s attachment: attachment in children and young people who are adopted from care, in care or at high risk of going into care (NG26)
Product type:
Guidance
Programme:
NICE guideline
Published:
25 November 2015
Maternal and child nutrition (PH11)
Product type:
Guidance
Programme:
Public health guideline
Last updated:
1 November 2014
Published:
26 March 2008
Contraceptive services for under 25s (PH51)
Product type:
Guidance
Programme:
Public health guideline
Published:
26 March 2014
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) (TA302)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 November 2013
Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (TA300)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 November 2013
Weight management: lifestyle services for overweight or obese children and young people (PH47)
Product type:
Guidance
Programme:
Public health guideline
Published:
23 October 2013
Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 July 2013
Social and emotional wellbeing: early years (PH40)
Product type:
Guidance
Programme:
Public health guideline
Published:
24 October 2012
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 December 2011
Food allergy in under 19s: assessment and diagnosis (CG116)
Product type:
Guidance
Programme:
Clinical guideline
Published:
23 February 2011
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 January 2011
Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)
Product type:
Guidance
Programme:
Clinical guideline
Published:
15 December 2010
Unintentional injuries in the home: interventions for under 15s (PH30)
Product type:
Guidance
Programme:
Public health guideline
Published:
24 November 2010
Unintentional injuries on the road: interventions for under 15s (PH31)
Product type:
Guidance
Programme:
Public health guideline
Published:
24 November 2010
Unintentional injuries: prevention strategies for under 15s (PH29)
Product type:
Guidance
Programme:
Public health guideline
Published:
24 November 2010
Bedwetting in under 19s (CG111)
Product type:
Guidance
Programme:
Clinical guideline
Published:
27 October 2010
Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 May 2010
Diarrhoea and vomiting caused by gastroenteritis in under 5s: diagnosis and management (CG84)
Product type:
Guidance
Programme:
Clinical guideline
Published:
22 April 2009
Physical activity for children and young people (PH17)
Product type:
Guidance
Programme:
Public health guideline
Published:
28 January 2009
Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years (TA131)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 November 2007
Serial transverse enteroplasty procedure (STEP) for bowel lengthening in parenteral nutrition-dependent children (IPG232)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
26 September 2007
Improving outcomes in children and young people with cancer (CSG7)
Product type:
Guidance
Programme:
Cancer service guideline
Published:
24 August 2005
Balloon dilatation of systemic to pulmonary arterial shunts in children (IPG77)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
28 July 2004
Balloon dilatation with or without stenting for pulmonary artery or non-valvar right ventricular outflow tract obstruction in children (IPG76)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
28 July 2004
Vagus nerve stimulation for refractory epilepsy in children (IPG50)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
24 March 2004
Inhaler devices for routine treatment of chronic asthma in older children (aged 5 to 15 years) (TA38)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 March 2002
Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma (TA10)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 August 2000
Servo-n with Neurally Adjusted Ventilatory Assist (NAVA) for babies and children (MIB163)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
26 October 2018
Next-generation sequencing panel for solid tumour cancers in children (MIB133)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
8 January 2018
Thora-3Di for assessing asthma in children (MIB122)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
2 October 2017
Mitochondrial disorders in children: Co-enzyme Q10 (ES11)
Product type:
Advice
Programme:
Evidence summary
Published:
28 March 2017
Mollii suit for spasticity (MIB100)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
28 March 2017
Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide (ES5)
Product type:
Advice
Programme:
Evidence summary
Published:
14 February 2017
Management of vomiting in children and young people with gastroenteritis: ondansetron (ESUOM34)
Product type:
Advice
Programme:
Evidence summary
Published:
7 October 2014
Promoting tolerance of enteral feeds in children and young people: domperidone (ESUOM18)
Product type:
Advice
Programme:
Evidence summary
Last updated:
30 September 2014
Published:
30 July 2013
Transition from children’s to adults’ services (QS140)
Product type:
Quality standard
Last updated:
14 December 2023
Published:
21 December 2016
Fever in under 5s (QS64)
Product type:
Quality standard
Last updated:
27 July 2022
Published:
24 July 2014
Urinary tract infection in children and young people (QS36)
Product type:
Quality standard
Last updated:
27 July 2022
Published:
16 July 2013
Vaccine uptake in under 19s (QS145)
Product type:
Quality standard
Last updated:
17 May 2022
Published:
2 March 2017
Diabetes in children and young people (QS125)
Product type:
Quality standard
Last updated:
31 March 2022
Published:
14 July 2016
Faltering growth (QS197)
Product type:
Quality standard
Published:
28 August 2020
Child abuse and neglect (QS179)
Product type:
Quality standard
Published:
12 February 2019
Developmental follow-up of children and young people born preterm (QS169)
Product type:
Quality standard
Published:
18 May 2018
Suspected cancer (QS124)
Product type:
Quality standard
Last updated:
5 December 2017
Published:
30 June 2016
Cerebral palsy in children and young people (QS162)
Product type:
Quality standard
Published:
10 October 2017
End of life care for infants, children and young people (QS160)
Product type:
Quality standard
Published:
12 September 2017
Haematological cancers (QS150)
Product type:
Quality standard
Published:
1 June 2017
Children’s attachment (QS133)
Product type:
Quality standard
Published:
12 October 2016
Intravenous fluid therapy in children and young people in hospital (QS131)
Product type:
Quality standard
Published:
21 September 2016
Early years: promoting health and wellbeing in under 5s (QS128)
Product type:
Quality standard
Published:
11 August 2016
Obesity: clinical assessment and management (QS127)
Product type:
Quality standard
Published:
4 August 2016
Bronchiolitis in children (QS122)
Product type:
Quality standard
Published:
22 June 2016
Food allergy (QS118)
Product type:
Quality standard
Published:
24 March 2016
Gastro-oesophageal reflux in children and young people (QS112)
Product type:
Quality standard
Published:
28 January 2016
Preventing unintentional injury in under 15s (QS107)
Product type:
Quality standard
Published:
14 January 2016
Bipolar disorder, psychosis and schizophrenia in children and young people (QS102)
Product type:
Quality standard
Published:
15 October 2015
Obesity in children and young people: prevention and lifestyle weight management programmes (QS94)
Product type:
Quality standard
Published:
23 July 2015
Nutrition: improving maternal and child nutrition (QS98)
Product type:
Quality standard
Published:
1 July 2015
Bedwetting in children and young people (QS70)
Product type:
Quality standard
Published:
18 September 2014
Constipation in children and young people (QS62)
Product type:
Quality standard
Published:
13 May 2014
Antisocial behaviour and conduct disorders in children and young people (QS59)
Product type:
Quality standard
Published:
17 April 2014
Cancer services for children and young people (QS55)
Product type:
Quality standard
Published:
27 February 2014
Depression in children and young people (QS48)
Product type:
Quality standard
Published:
30 September 2013
Atopic eczema in under 12s (QS44)
Product type:
Quality standard
Published:
5 September 2013
Headaches in over 12s (QS42)
Product type:
Quality standard
Published:
28 August 2013
Looked-after children and young people (QS31)
Product type:
Quality standard
Published:
3 April 2013
Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
18 December 2024
Maternal and child nutrition
Status:
In development
Programme:
NICE guideline
Expected publication date:
15 January 2025
Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment
Status:
In development | In consultation
Programme:
Health technology evaluation
Consultation end date:
17 December 2024
Expected publication date:
24 April 2025
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
25 June 2025
Spineform Hemibridge endoscopic vertebral stapling to reduce curvature in the growing scoliotic spine in children
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
School-based interventions: physical and mental health and wellbeing promotion
Status:
In development
Expected publication date:
TBC
Pain management (young people and adults)
Status:
Awaiting development
Expected publication date:
TBC
VTS-270 for treating Niemann-Pick type C1 [ID1267]
Status:
In development
Programme:
Highly specialised technologies guidance
Expected publication date:
TBC
Infant, children and young people's experience of health care
Status:
Awaiting development
Expected publication date:
TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Omburtamab for treating relapsed neuroblastoma [ID1664]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Children and young people with disabilities and severe complex needs: integrated health and social care support
Status:
Awaiting development
Expected publication date:
TBC
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
26 November 2024
Expected publication date:
TBC
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Leriglitazone for treating andrenoleukodystrophy [ID3903]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TS ID 10085]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TS ID 10639]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Darunavir plus cobicistat fixed dose combination for paediatric human immunodeficiency virus 1 infection [TS ID 10722]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dupilumab for children with severe atopic dermatitis [TS ID 10434]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dulaglutide for treating type 2 diabetes in children and young people TS ID 10660
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mirabegron for treating neurogenic detrusor overactivity in people aged 3 to 17 TS ID 10730
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vamorolone for treating Duchenne muscular dystrophy [ID4024]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 TS ID 11778
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Crizotinib for treating ALK-positive anaplastic large cell lymphoma or inflammatory myofibroblastic tumour in people 6 to 17 years [TS ID 10574]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Somapacitan for treating growth hormone deficiency in children [ID6178]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Crizanlizumab for preventing recurrent vaso-occlusive crises in sickle cell disease in young people aged 12 to 17 TS ID 10766
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Macitentan for treating pulmonary arterial hypertension in people 1 month to 17 years TS ID 11805
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Evinacumab for treating homozygous familial hypercholesterolemia in children aged 5 to 11 TS ID 11806
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Subcutaneous belimumab for treating systemic lupus erythematosus in children aged 5 to 17 TS ID 11828
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ceftobiprole medocaril for treating community- or hospital-acquired pneumonia in people 3 months to 17 years TS ID 11819
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Setmelanotide for treating obesity caused by a rare genetic disorder in children aged 2 to 5 TS ID 11827
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years TS ID 10237
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant TS ID 11868
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Canagliflozin for treating type 2 diabetes in people 10 to 17 years TS ID 11888
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]
Status:
In development
Programme:
Highly specialised technologies guidance
Expected publication date:
TBC
Leriglitazone for treating X-linked andrenoleukodystrophy TS ID 9996
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease in people 12 to 17 years TS ID 11887
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over ID6372
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older TSID 11995
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy TSID 11996
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vosoritide for treating achondroplasia in people 4 months and over ID6488
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years TSID 12002
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ustekinumab for the treatment of moderately to severely active Crohn's disease in children [TS ID 11955]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years TSID 12049
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Digital support for children and young people with eating disorders:early value assessment
Status:
Awaiting development
Programme:
Health technology evaluation
Expected publication date:
TBC